NAS receives non-compliance notice from Nasdaq

Nasdaq has indicated that North American Scientific (NAS) has failed to regain compliance with the minimum $1 bid price per share requirement within the 180 calendar-day compliance period, which ended on April 2.

Nasdaq also noted that the Chatsworth, Calif.-based NAS is not eligible for an additional 180 calendar-day compliance period given that it does not meet the Nasdaq capital market initial inclusion criteria of $15 million market value of publicly held shares.

Therefore, the company's common stock is subject to delisting from the Nasdaq capital market at the opening of business on April 15. 

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.